If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
211
results.
Updated on
25/12/2025 [06:52:00]
Results 200 to 211 of 211
Absstract of: CN120603581A
An aqueous dispersion having an aqueous mobile phase and a dispersed phase is described; wherein the dispersed phase comprises a lipid mixture comprising a cationically ionizable lipid; and the aqueous mobile phase comprises anions of an aqueous acid; wherein the aqueous dispersion is substantially free of inorganic cations, organic solvents, and RNA. Methods of making the aqueous dispersions, nucleic acid-lipid particles and methods of making them using the aqueous dispersions, and their use in medicine are disclosed.
Absstract of: CN120603581A
An aqueous dispersion having an aqueous mobile phase and a dispersed phase is described; wherein the dispersed phase comprises a lipid mixture comprising a cationically ionizable lipid; and the aqueous mobile phase comprises anions of an aqueous acid; wherein the aqueous dispersion is substantially free of inorganic cations, organic solvents, and RNA. Methods of making the aqueous dispersions, nucleic acid-lipid particles and methods of making them using the aqueous dispersions, and their use in medicine are disclosed.
Absstract of: WO2024161249A1
Compounds are provided having the following structure Formula (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein G1, G2, G3, L1, L2, R1, R2, R3, W and Y are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a nucleic acid, compositions comprising the compounds and methods for their use and preparation are also provided.
Absstract of: AU2024213596A1
A method of treating a pulmonary condition in a subject having or at risk of having the pulmonary condition generally includes administering to the subject a therapeutic composition in an amount effective to treat the pulmonary' condition. Generally, the therapeutic composition includes purified exosome product (PEP) exosomes and a pharmaceutically acceptable carrier. In one or more embodiments, the PEP exosomes are modified to include at least one exogenous active agent. In one or more embodiments, the therapeutic composition is formulated for delivery directly to a potion of tire pulmonary tract.
Absstract of: AU2024214423A1
Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (e.g., HSC), and methods of making and using such lipids and targeted lipid. nanoparticles.
Absstract of: MX2025008776A
A composition for treating hyperprocalcitonemia is described. The composition comprises a lipophilic or hydrophobic component, an amphiphilic emulsifier, a polar liquid carrier, and with or without one or more electrolytes, where the amphiphilic emulsifier forms micelles having a lipophilic or hydrophobic core comprising the lipophilic or hydrophobic component in the polar liquid carrier, and /or liposomes organized as a lipid bilayer and/or other particle configurations.
Absstract of: EP4660189A1
The present invention addresses the problem of creating a carbamoyl lipid or a urea lipid each having a cyclic amino and developing lipid nanoparticles, and thereby providing a pharmaceutical composition for nucleic acid therapeutics and others. The present inventors have discovered a compound that is a carbamoyl lipid or a urea lipid each having a cyclic amino or a salt of the compound, and have studied on lipid nanoparticles that can be used in various pharmaceutical compositions. As a result, it was revealed that lipid nanoparticles can be formed using the compound of the present invention, which is a lipid, or a salt of the compound. By using the lipid nanoparticles containing the carbamoyl lipid or the urea lipid each having a cyclic amino according to the present invention, it is expected that a pharmaceutical composition containing the lipid nanoparticles each encapsulating a nucleic acid therein can be used as a prophylactic or therapeutic agent for astrocyte-related diseases.
Absstract of: WO2024161416A1
The present invention relates to a caprolactone based biodegradable compound(s) of formula (I) comprising photo-cleavable groups, photo-sensitive groups or combination thereof. The present invention also relates to a method of preparing the caprolactone based biodegradable compound(s) of formula (I). In addition, the present invention relates the caprolactone biodegradable compound(s) of formula (I) useful in the pharmaceutical field in controlled release systems, drug delivery system/carrier, bioimaging, implants, etc.
Absstract of: US2025352490A1
Particles made of a polymeric matrix having associated therewith a therapeutically active agent usable in treating a medical condition associated with an overexpression of P-selectin in a subject in need thereof and featuring a P-selectin selective targeting moiety represented by Formula I as defined and described in the specification and claims, compositions comprises these particles and uses thereof, are provided.
Absstract of: WO2024161391A1
Nanoparticles comprising an outer surface covalently conjugated to 1,4-Bis(1,4,8,11-tetraazacyclotetradecan-l-yl)methylbenzene (AMD3100) or a derivative thereof capable of binding to C-X-C chemokine receptor type 4 (CXCR4) are provided. Methods for of treating a CXCR4 positive cancer, such as multiple myeloma or acute myeloid leukemia, in a subject in need thereof, methods of determining suitability for treatment and methods of covalently linking a molecule comprising a secondary amine to a lipid nanoparticle, are also provided.
Nº publicación: EP4658801A1 10/12/2025
Applicant:
UNIV CALIFORNIA [US]
HARVARD COLLEGE [US]
UNIV MEXICO NAC AUTONOMA [MX]
UNIV AUTONOMO DE SAN LUIS POTOSI [MX]
The Regents of the University of California,
Harvard College,
Universidad Nacional Aut\u00F3noma De M\u00E9xico,
Universidad Aut\u00F3nomo de San Luis Potos\u00ED
Absstract of: WO2024163754A1
The invention provides compositions of matter comprising a lipid enveloped virus capsid protein and a ribonucleic acid, as well as methods for using such compositions. In illustrative compositions, the lipid enveloped virus capsid protein envelops the ribonucleic acid so as to for a capsid that can inhibit the degradation of the ribonucleic acid (e.g. by RNAses). A method of delivering a ribonucleic acid into the cytoplasm of a mammalian cell is also provided. Typically, the method comprises the steps of combining the mammalian cell with a composition of matter described herein under conditions selected to allow the lipid enveloped virus capsid to contact the mammalian cell and deliver the ribonucleic acid into the cytoplasm of a mammalian cell.
BOPI
Electronic site
